Exclusive: Moderna's Vaccine Approval Delayed Due to FDA Administrative Constraints, What's Cooking at the Agency?

FDA Playing Hard to Get

Oh the FDA and its administrative constraints always keeping us on our toes! Moderna's RSV vaccine approval has been pushed back to the end of May leaving everyone hanging on the edge of their seats.

The Waiting Game

Investors are anxiously waiting for the FDA's decision hoping Moderna can bounce back after the Covid rollercoaster. Will the RSV shot be the company's next big hit?

The Power of Three

Move over Pfizer and GSK Moderna's RSV vaccine is ready to make its mark as the third contender in the market. Let the vaccine wars begin!

Advisory Panel Drama

The CDC advisory panel will have the final say on Moderna's RSV shot in June. Will they give it the green light? Stay tuned for the next episode of 'Vaccine Approval Wars'.

From Covid to RSV

Moderna's mRNA platform is proving to be a game changer beyond Covid. With RSV cancer and norovirus on the horizon the biotech company is cooking up quite the mRNA feast!

Investors' Rollercoaster Ride

Investors are riding the Moderna rollercoaster up 20% this year down 45% last year. Will the RSV vaccine approval be the ticket to the moon? To infinity and beyond!